ECB-ART-50098
Cancer J
2013 Jan 01;193:238-46. doi: 10.1097/PPO.0b013e31829a68eb.
Show Gene links
Show Anatomy links
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
Laszlo A
,
Thotala D
,
Hallahan DE
.
???displayArticle.abstract???
Approximately one third of patients with non-small cell lung cancer have unresectable stage IIIA or stage IIIB disease; combined cytotoxic chemotherapy and radiation therapy delivered concurrently has been established as the standard treatment for such patients. Despite many clinical trials that tested several different radiochemotherapy combinations, it seems that a plateau of efficiencies at the acceptable risk of complications has been reached. Clinical studies indicate that the improved efficacy of radiochemotherapy is associated with the radiosensitizing effects of chemotherapy. Improvement of outcomes of this combined modality by developing novel radiosensitizers is a viable therapeutic strategy. In addition to causing cell death, ionizing radiation also induces a many-faceted signaling response, which activates numerous prosurvival pathways that lead to enhanced proliferation in the endothelial cells and increased vascularization in tumors. Radiation at doses used in the clinic activates cytoplasmic phospholipase A2, leading to increased production of arachidonic acid and lysophosphatidylcholine. The former is the initial step in the generation of eicosanoids, while the later is the initial step in the formation of lysophosphatidic acid, leading to the activation of inflammatory pathways. The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) is member of the insulin superfamily of receptor tyrosine kinases. The EML4-ALK fusion gene appears unique to lung cancer and signals through extracellular signal regulated kinase and phosphoinositide 3-kinase. Heat shock protein 90 (Hsp90) is often overexpressed and present in an activated multichaperone complex in cancer cells, and it is now regarded as essential for malignant transformation and progression. In this review we focus on radiosensitizing strategies involving the targeting of membrane phospholipids, EML4-ALK, and Hsp90 with specific inhibitors and briefly discuss the combination of radiation with antivascular agents.
???displayArticle.pubmedLink??? 23708071
???displayArticle.pmcLink??? PMC3718064
???displayArticle.link??? Cancer J
???displayArticle.grants??? [+]
R01 CA089674 NCI NIH HHS , R01 CA112385 NCI NIH HHS , R01 CA140220 NCI NIH HHS , R21 CA170169 NCI NIH HHS
References [+] :
Acquaviva,
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
2012, Pubmed
Acquaviva, Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. 2012, Pubmed
Agarwal, Eicosanoids in inflammation and cancer: the role of COX-2. 2009, Pubmed
Aggarwal, Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? 2012, Pubmed
Anderson, Combined modality therapy for stage III non-small-cell lung cancer. 2010, Pubmed
Baas, Chemoradiation therapy in nonsmall cell lung cancer. 2011, Pubmed
Bang, The potential for crizotinib in non-small cell lung cancer: a perspective review. 2011, Pubmed , Echinobase
Baumforth, Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. 2005, Pubmed
Bergers, The role of pericytes in blood-vessel formation and maintenance. 2005, Pubmed
Blumenschein, Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). 2012, Pubmed
Bonventre, Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. 1997, Pubmed
Brabender, Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. 2002, Pubmed
Camidge, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. 2012, Pubmed
Camphausen, Inhibition of Hsp90: a multitarget approach to radiosensitization. 2007, Pubmed
Chakraborti, Phospholipase A(2) isoforms: a perspective. 2003, Pubmed
Chang, Identification and development of mPGES-1 inhibitors: where we are at? 2011, Pubmed
Chargari, Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation. 2013, Pubmed
Chiarle, The anaplastic lymphoma kinase in the pathogenesis of cancer. 2008, Pubmed
Choi, LPA receptors: subtypes and biological actions. 2010, Pubmed
Choi, Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. 2008, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Choy, Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? 2003, Pubmed
Christensen, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. 2007, Pubmed
Ciccia, The DNA damage response: making it safe to play with knives. 2010, Pubmed
Corre, Plasma membrane signaling induced by ionizing radiation. 2010, Pubmed
Curran, Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. 2011, Pubmed
Dent, Stress and radiation-induced activation of multiple intracellular signaling pathways. 2003, Pubmed
Dent, Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits. 1996, Pubmed
Deorukhkar, Targeting inflammatory pathways for tumor radiosensitization. 2010, Pubmed
Djuzenova, Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia. 2012, Pubmed
Doebele, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012, Pubmed
Eccles, NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. 2008, Pubmed
Ellis, Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. 2012, Pubmed
Garon, The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. 2013, Pubmed
Geng, Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. 2001, Pubmed
Gore, Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. 2011, Pubmed
Groen, Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. 2011, Pubmed
Gulbins, Raft ceramide in molecular medicine. 2003, Pubmed
Haasbeek, Radiotherapy for lung cancer: clinical impact of recent technical advances. 2009, Pubmed
Han, 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. 2002, Pubmed
Hanahan, Accessories to the crime: functions of cells recruited to the tumor microenvironment. 2012, Pubmed
Hanahan, The hallmarks of cancer. 2000, Pubmed
Hanahan, Hallmarks of cancer: the next generation. 2011, Pubmed
Hartmann, Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. 2013, Pubmed
Herbert, Activation of cytosolic phospholipase A2-{alpha} as a novel mechanism regulating endothelial cell cycle progression and angiogenesis. 2009, Pubmed
Heuckmann, ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011, Pubmed
Hida, Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. 1998, Pubmed
Horn, Targeting the eicosanoid pathway in non-small-cell lung cancer. 2009, Pubmed
Jain, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. 2005, Pubmed
Jhaveri, Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. 2012, Pubmed
Jiang, Cox-2 in non-small cell lung cancer: a meta-analysis. 2013, Pubmed
Kamal, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. 2003, Pubmed
Katayama, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012, Pubmed
Katayama, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011, Pubmed , Echinobase
Kishi, Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. 2006, Pubmed
Kleibeuker, Combining angiogenesis inhibition and radiotherapy: a double-edged sword. 2012, Pubmed
Koch, Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. 2011, Pubmed
Koh, Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. 2012, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Laga, Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. 2005, Pubmed
Leach, Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. 2001, Pubmed
Lee, Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. 1996, Pubmed
Liao, Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? 2007, Pubmed
Linkous, Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. 2009, Pubmed
Linkous, Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. 2010, Pubmed
Linkous, Cytosolic phospholipase A2 as a mediator of disease pathogenesis. 2010, Pubmed
Liu, Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. 2001, Pubmed
Liu, Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. 2009, Pubmed
Luo, Principles of cancer therapy: oncogene and non-oncogene addiction. 2009, Pubmed
McDermott, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008, Pubmed
Mikkelsen, Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. 2003, Pubmed
Mutter, A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. 2009, Pubmed
Nam, Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. 2001, Pubmed
Neckers, Hsp90 molecular chaperone inhibitors: are we there yet? 2012, Pubmed
Nishimasu, Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. 2011, Pubmed
Normant, The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. 2011, Pubmed , Echinobase
Palma, Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. 2011, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Pearl, The Hsp90 molecular chaperone: an open and shut case for treatment. 2008, Pubmed
Petkova, Overexpression of cyclooxygenase-2 in non-small cell lung cancer. 2004, Pubmed
Pick, High HSP90 expression is associated with decreased survival in breast cancer. 2007, Pubmed
Pidgeon, Lipoxygenase metabolism: roles in tumor progression and survival. 2007, Pubmed
Prokazova, Effect of lysophosphatidylcholine on transmembrane signal transduction. 1998, Pubmed
Raza, Pericytes and vessel maturation during tumor angiogenesis and metastasis. 2010, Pubmed
Robinson, The treatment of early-stage disease. 2010, Pubmed
Roskoski, Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. 2013, Pubmed
Salama, New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 2013, Pubmed
Sang, Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. 2013, Pubmed
Sasaki, The biology and treatment of EML4-ALK non-small cell lung cancer. 2010, Pubmed , Echinobase
Sasaki, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. 2011, Pubmed
Schleicher, Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. 2011, Pubmed
Sequist, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. 2010, Pubmed
Shaw, Targeting anaplastic lymphoma kinase in lung cancer. 2011, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shimamura, Heat shock protein 90 inhibition in lung cancer. 2008, Pubmed
Siegel, Cancer statistics, 2013. 2013, Pubmed
So, LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). 2005, Pubmed
Socinski, A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. 2013, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Soda, A mouse model for EML4-ALK-positive lung cancer. 2008, Pubmed
Steinauer, Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. 2000, Pubmed
Stephans, Stereotactic body radiotherapy for stage I non-small cell lung cancer. 2012, Pubmed
Stinchcombe, Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. 2012, Pubmed
Stingl, Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. 2010, Pubmed
Sun, ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. 2013, Pubmed
Szumiel, Intrinsic radiation sensitivity: cellular signaling is the key. 2008, Pubmed
Taipale, HSP90 at the hub of protein homeostasis: emerging mechanistic insights. 2010, Pubmed
Thariat, Past, present, and future of radiotherapy for the benefit of patients. 2013, Pubmed
Tonks, Protein tyrosine phosphatases and the control of cellular signaling responses. 1996, Pubmed
Tracy, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. 2004, Pubmed
Travers, HSP90 inhibition: two-pronged exploitation of cancer dependencies. 2012, Pubmed
Trepel, Targeting the dynamic HSP90 complex in cancer. 2010, Pubmed
Trinchieri, Cancer and inflammation: an old intuition with rapidly evolving new concepts. 2012, Pubmed
Tumati, Effect of PF-02341066 and radiation on non-small cell lung cancer cells. 2013, Pubmed , Echinobase
Ueno, Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. 2012, Pubmed
Valerie, Radiation-induced cell signaling: inside-out and outside-in. 2007, Pubmed
Wang, Eicosanoids and cancer. 2010, Pubmed
Weinstein, Oncogene addiction. 2008, Pubmed
Weinstein, Cancer. Addiction to oncogenes--the Achilles heal of cancer. 2002, Pubmed
Weiser-Evans, Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. 2009, Pubmed
Whitesell, HSP90 and the chaperoning of cancer. 2005, Pubmed
Whitesell, Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. 1994, Pubmed
Whitesell, HSP90 as a platform for the assembly of more effective cancer chemotherapy. 2012, Pubmed
Workman, Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. 2007, Pubmed
Xie, The performance of a bone-derived scaffold material in the repair of critical bone defects in a rhesus monkey model. 2007, Pubmed
Xu, Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. 2010, Pubmed
Yang, Investigation of radiation-induced transcriptome profile of radioresistant non-small cell lung cancer A549 cells using RNA-seq. 2013, Pubmed
Yap, Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012, Pubmed
Yazlovitskaya, Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. 2008, Pubmed
Zaidi, The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. 2012, Pubmed
van Meeteren, Regulation and biological activities of the autotaxin-LPA axis. 2007, Pubmed